{"id":"https://openalex.org/W2908220784","doi":"https://doi.org/10.1182/blood-2018-99-119306","title":"Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2mutations after Intensive Chemotherapy","display_name":"Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2mutations after Intensive Chemotherapy","publication_year":2018,"publication_date":"2018-11-29","ids":{"openalex":"https://openalex.org/W2908220784","doi":"https://doi.org/10.1182/blood-2018-99-119306","mag":"2908220784"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2018-99-119306","doi":"https://doi.org/10.1182/blood-2018-99-119306","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2018-99-119306","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5067600974","display_name":"Swapna Thota","orcid":"https://orcid.org/0000-0002-4216-1414","observed_orcids":["https://orcid.org/0000-0002-4216-1414"]},"institutions":[{"id":"https://openalex.org/I1292894508","display_name":"Roswell Park Comprehensive Cancer Center","ror":"https://ror.org/0499dwk57","country_code":"US","type":"facility","lineage":["https://openalex.org/I1292894508"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Swapna Thota","raw_affiliation_strings":["Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY","institution_ids":["https://openalex.org/I1292894508"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114429797","display_name":"Bhumika J. Patel","orcid":"https://orcid.org/0009-0008-4984-7751","observed_orcids":["https://orcid.org/0009-0008-4984-7751"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bhumika J. Patel","raw_affiliation_strings":["Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016810759","display_name":"Hetty E. Carraway","orcid":"https://orcid.org/0000-0001-5241-3614","observed_orcids":["https://orcid.org/0000-0001-5241-3614"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hetty E. Carraway","raw_affiliation_strings":["Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060452476","display_name":"Elizabeth A. Griffiths","orcid":"https://orcid.org/0000-0002-0288-8248","observed_orcids":["https://orcid.org/0000-0002-0288-8248"]},"institutions":[{"id":"https://openalex.org/I1292894508","display_name":"Roswell Park Comprehensive Cancer Center","ror":"https://ror.org/0499dwk57","country_code":"US","type":"facility","lineage":["https://openalex.org/I1292894508"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elizabeth A. Griffiths","raw_affiliation_strings":["Roswell Park Comprehensive Cancer Center, Buffalo, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Roswell Park Comprehensive Cancer Center, Buffalo, NY","institution_ids":["https://openalex.org/I1292894508"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078571628","display_name":"Amanda Przespolewski","orcid":"https://orcid.org/0000-0002-8241-8288","observed_orcids":["https://orcid.org/0000-0002-8241-8288"]},"institutions":[{"id":"https://openalex.org/I1292894508","display_name":"Roswell Park Comprehensive Cancer Center","ror":"https://ror.org/0499dwk57","country_code":"US","type":"facility","lineage":["https://openalex.org/I1292894508"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amanda Przespolewski","raw_affiliation_strings":["Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY","institution_ids":["https://openalex.org/I1292894508"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046140518","display_name":"James E. Thompson","orcid":"https://orcid.org/0000-0003-3030-7559","observed_orcids":["https://orcid.org/0000-0003-3030-7559"]},"institutions":[{"id":"https://openalex.org/I1292894508","display_name":"Roswell Park Comprehensive Cancer Center","ror":"https://ror.org/0499dwk57","country_code":"US","type":"facility","lineage":["https://openalex.org/I1292894508"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James E. Thompson","raw_affiliation_strings":["Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY","institution_ids":["https://openalex.org/I1292894508"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059910743","display_name":"Teodora Kuzmanovic","orcid":"https://orcid.org/0000-0003-2194-293X","observed_orcids":["https://orcid.org/0000-0003-2194-293X"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Teodora Kuzmanovic","raw_affiliation_strings":["Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086233229","display_name":"Aziz Nazha","orcid":"https://orcid.org/0000-0002-6695-7994","observed_orcids":["https://orcid.org/0000-0002-6695-7994"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aziz Nazha","raw_affiliation_strings":["Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089637417","display_name":"Shimoli Vipul Barot","orcid":"https://orcid.org/0000-0002-5313-9992","observed_orcids":["https://orcid.org/0000-0002-5313-9992"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shimoli Vipul Barot","raw_affiliation_strings":["Leukemia, Cleveland CLinic, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia, Cleveland CLinic, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112104644","display_name":"Cassandra M. Hirsch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Cassandra M. Hirsch","raw_affiliation_strings":["Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022299669","display_name":"Bartlomiej P. Przychodzen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Bartlomiej P. Przychodzen","raw_affiliation_strings":["Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102826236","display_name":"Sudipto Mukherjee","orcid":"https://orcid.org/0000-0002-8325-2603","observed_orcids":["https://orcid.org/0000-0002-8325-2603","https://orcid.org/0009-0002-0717-6319"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sudipto Mukherjee","raw_affiliation_strings":["Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058490888","display_name":"Meghan Scully","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Meghan Scully","raw_affiliation_strings":["Clevaland Clinic, Cleveland,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clevaland Clinic, Cleveland,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023728016","display_name":"Aaron Thomas Gerds","orcid":"https://orcid.org/0000-0002-3422-1309","observed_orcids":["https://orcid.org/0000-0002-3422-1309"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aaron T. Gerds","raw_affiliation_strings":["Cleveland Clinic Taussig Cancer Institute, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic Taussig Cancer Institute, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082944296","display_name":"Anjali S. Advani","orcid":"https://orcid.org/0000-0003-0015-5902","observed_orcids":["https://orcid.org/0000-0003-0015-5902"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anjali S. Advani","raw_affiliation_strings":["Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Taussig Cancer Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055740968","display_name":"Mikkael Aaron Sekeres","orcid":"https://orcid.org/0000-0003-2009-6524","observed_orcids":["https://orcid.org/0000-0003-2009-6524"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mikkael A. Sekeres","raw_affiliation_strings":["Leukemia & Myeloid Disorders Program, Cleveland Clinic, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia & Myeloid Disorders Program, Cleveland Clinic, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041448618","display_name":"Manja Meggendorfer","orcid":"https://orcid.org/0000-0002-9038-3265","observed_orcids":["https://orcid.org/0000-0002-9038-3265"]},"institutions":[{"id":"https://openalex.org/I4210093919","display_name":"Munich Leukemia Laboratory (Germany)","ror":"https://ror.org/00smdp487","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210093919"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Manja Meggendorfer","raw_affiliation_strings":["MLL Munich Leukemia Laboratory, Munich, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MLL Munich Leukemia Laboratory, Munich, Germany","institution_ids":["https://openalex.org/I4210093919"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038660651","display_name":"Eunice S. Wang","orcid":"https://orcid.org/0000-0002-8644-0968","observed_orcids":["https://orcid.org/0000-0002-8644-0968"]},"institutions":[{"id":"https://openalex.org/I1292894508","display_name":"Roswell Park Comprehensive Cancer Center","ror":"https://ror.org/0499dwk57","country_code":"US","type":"facility","lineage":["https://openalex.org/I1292894508"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eunice S. Wang","raw_affiliation_strings":["Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY","institution_ids":["https://openalex.org/I1292894508"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5085974329","display_name":"Jaroslaw Pawel Maciejewski","orcid":"https://orcid.org/0000-0002-6837-4346","observed_orcids":["https://orcid.org/0000-0002-6837-4346"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jaroslaw P. Maciejewski","raw_affiliation_strings":["Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5022299669","https://openalex.org/A5058490888","https://openalex.org/A5059910743","https://openalex.org/A5112104644"],"corresponding_institution_ids":["https://openalex.org/I1316902750"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"132","issue":"Supplement 1","first_page":"1389","last_page":"1389"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/idh1-mutation","display_name":"IDH1 mutation","score":0.8830000162124634},{"id":"https://openalex.org/keywords/idh2-mutation","display_name":"IDH2 mutation","score":0.9990000128746033},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9210000038146973},{"id":"https://openalex.org/keywords/myelodysplastic-syndrome","display_name":"myelodysplastic syndrome","score":0.9580000042915344},{"id":"https://openalex.org/keywords/myeloproliferative-neoplasms","display_name":"myeloproliferative neoplasms","score":0.9890000224113464},{"id":"https://openalex.org/keywords/intensive-chemotherapy","display_name":"intensive chemotherapy","score":0.9369999766349792},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.7889999747276306},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9700000286102295},{"id":"https://openalex.org/keywords/relapse","display_name":"relapse","score":0.6460000276565552},{"id":"https://openalex.org/keywords/complete-remission","display_name":"complete remission","score":0.4959999918937683},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.6209999918937683},{"id":"https://openalex.org/keywords/idh-inhibitors","display_name":"IDH inhibitors","score":0.5910000205039978},{"id":"https://openalex.org/keywords/enasidenib","display_name":"enasidenib","score":0.7900000214576721},{"id":"https://openalex.org/keywords/ivosidenib","display_name":"ivosidenib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/risk-stratification","display_name":"risk stratification","score":0.6370000243186951}],"concepts":[{"id":"https://openalex.org/C127848430","wikidata":"https://www.wikidata.org/wiki/Q18027543","display_name":"IDH1","level":4,"score":0.8214387893676758},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6895216703414917},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6699772477149963},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6459646224975586},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5011203289031982},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.49688294529914856},{"id":"https://openalex.org/C2779282312","wikidata":"https://www.wikidata.org/wiki/Q1956561","display_name":"Myeloid","level":2,"score":0.46861347556114197},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.41031157970428467},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.32720816135406494},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.12802955508232117},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.12536340951919556},{"id":"https://openalex.org/C501734568","wikidata":"https://www.wikidata.org/wiki/Q42918","display_name":"Mutation","level":3,"score":0.09291931986808777},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2018-99-119306","doi":"https://doi.org/10.1182/blood-2018-99-119306","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2018-99-119306","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3169053406","https://openalex.org/W4310126165","https://openalex.org/W2952146319","https://openalex.org/W2914819118","https://openalex.org/W1847894796","https://openalex.org/W2952434081","https://openalex.org/W2984640173","https://openalex.org/W4389229751","https://openalex.org/W7108440648","https://openalex.org/W3196488902"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"AML":[2,27,124,183,311,490],"and":[3,15,33,78,191,212,226,239,304,375,399,417,452,458,476,482,503,524,533],"MDS":[4,185],"are":[5,30,90,115,570],"heterogeneous":[6],"myeloid":[7],"neoplasias":[8],"(MN)":[9],"characterized":[10],"by":[11],"varied":[12],"pathogenic":[13],"mechanisms":[14],"associated":[16],"with":[17,86,108,177,326,360,515,536,542],"mixed":[18],"clinical":[19,113],"outcome.":[20],"Five-year":[21],"overall":[22,345,472,507,565],"survival":[23,228,473,508,566],"rates":[24,355],"for":[25,34,48,84,122,155,197,218,245,256,358,405,445,474,509,567],"younger":[26,290,386],"patients":[28,85,171,247,323,359,419,491],"(pts)":[29],"between":[31],"40-50%":[32],"elderly":[35],"pts,":[36],"a":[37,153,178,266,271,391],"dismal":[38],"10%.":[39],"Until":[40],"recently,":[41],"molecular":[42],"information":[43],"has":[44],"informed":[45],"risk":[46,310],"stratification":[47],"MN":[49,64,87,147,479,569],"patients,":[50,263],"but":[51],"targeted":[52,208,537],"therapies":[53,338,544],"were":[54,195,216,254,289,324,341,356,443,459],"limited":[55],"(i.e":[56],"ckit,":[57],"flt3":[58],"inhibitors).":[59],"Clinical":[60],"characterization":[61],"of":[62,66,73,97,110,119,139,144,165,181,200,241,313,321,415,430,561,593,606,621,669,680,691,702,724,742,759,771,795,815],"IDH1/2mutant":[63,182,554],"is":[65],"particular":[67],"interest":[68],"since":[69],"the":[70,82,94,117,140,163,198,261,428,506,546,559],"recent":[71],"availability":[72],"specific":[74],"IDH1/2inhibitors":[75],"(i.e.,":[76],"enasidenib":[77],"ivosidenib).":[79],"Datasets":[80],"describing":[81],"outcome":[83],"harboring":[88],"IDH1/2mutations":[89],"critical":[91],"to":[92,136,151,222,236,248,307,349,366,370,395,436,440,462,493,501,527,548],"inform":[93],"potential":[95,547],"utility":[96],"these":[98,322,551],"novel":[99],"IDH":[100,120,145,166,510],"inhibitors":[101,539],"as":[102],"single":[103],"agents":[104,332],"or":[105,187,334,595,608,623,671,682,693,704,726,744,761,773,797,817],"in":[106,149,158,273,283,377,522,540,553],"combination":[107,532],"standard":[109],"care.":[111],"Ongoing":[112,531],"trials":[114],"investigating":[116],"addition":[118],"inhibition":[121],"upfront":[123],"therapy.":[125],"In":[126],"this":[127],"retrospective":[128],"study,":[129],"we":[130],"combined":[131],"cohorts":[132],"from":[133,172],"three":[134,173],"institutions":[135],"enable":[137],"reporting":[138],"largest":[141],"cohort":[142],"(N=425)":[143],"mutated":[146,488,511],"pts":[148,387,512],"order":[150],"establish":[152],"baseline":[154],"therapeutic":[156,529],"outcomes":[157,552],"an":[159,590,603,618,666,677,688,699,721,739,756,768,792,812],"era":[160],"which":[161],"pre-dates":[162],"availability/addition":[164],"inhibitors.":[167],"Methods:We":[168],"identified":[169],"425":[170,262],"large":[174],"academic":[175],"centers":[176],"confirmed":[179],"diagnosis":[180],"(n=387),":[184],"(n=29)":[186,333],"MPN":[188],"(n=9).":[189],"Blood":[190],"bone":[192],"marrow":[193],"samples":[194],"analyzed":[196,427],"presence":[199],"recurrent":[201],"somatic":[202,432],"mutations":[203,282,433,457,521],"using":[204],"NGS":[205],"based":[206],"multi-gene":[207],"sequencing":[209],"panels.":[210],"Demographic":[211],"disease":[213],"related":[214],"variables":[215],"annotated":[217],"initial":[219,350,499],"treatment,":[220],"response":[221,251,346,393,435],"therapy":[223,351,407,442],"(IWG":[224],"criteria)":[225],"subsequent":[227],"details":[229,253],"(overall":[230],"survival,":[231],"progression":[232],"free":[233],"survival).":[234],"Time":[235],"first":[237],"relapse":[238],"duration":[240],"remission":[242],"was":[243,352,373,408,513],"collected":[244],"107":[246],"date.":[249],"Comprehensive":[250],"assessment":[252],"available":[255],"234":[257],"patients.":[258],"Results:":[259],"Of":[260],"165":[264],"had":[265,270,280,316,390],"mutation":[267,272],"inIDH1and":[268],"264":[269],"IDH2(82%":[274],"IDH2R140,":[275],"18%":[276],"R172K).":[277],"Four":[278],"cases":[279,288,293,315,380],"co-occurring":[281,431],"IDH1":[284,475],"&":[285],"IDH2.":[286],"IDH1mutant":[287],"than":[291,517],"IDH2mutant":[292,379],"(62":[294],"vs.":[295,466],"65":[296],"years,":[297],"p=0.05),":[298],"predominantly":[299],"male":[300],"(50%":[301],"vs.38%,":[302],"p=0.01)":[303],"more":[305],"likely":[306,461],"have":[308,426,463,494],"intermediate":[309],"(68%":[312],"IDH1/IDH2mutant":[314],"normal":[317],"karyotype).":[318],"A":[319],"majority":[320],"treated":[325],"cytarabine-based":[327],"intensive":[328,337,371,396,437,441,502],"chemotherapy":[329,372,397],"(n=362).":[330],"Hypomethylating":[331],"other":[335],"less":[336,460],"(n=":[339],"27)":[340],"also":[342],"used.":[343],"The":[344,403,470],"rate":[347,394],"(ORR)":[348],"65%.":[353],"Response":[354,369],"similar":[357],"both":[361],"IDH1and":[362,378],"IDH2mutation":[363],"(i.e,":[364],"66%":[365],"any":[367],"therapy).":[368],"68%":[374],"64%":[376],"respectively.":[381,485],"As":[382],"expected":[383,518],"IDH1/2":[384,487,538],"mutant":[385,478],"(<60":[388],"years)":[389],"higher":[392],"(81%":[398],"80":[400],"%":[401],"respectively).":[402],"ORR":[404],"HMA":[406],"73%":[409],"(64%":[410],"IDH1,":[411],"80%":[412],"IDH2mutants).":[413],"34%":[414],"IDH1mutants":[416],"30%IDH2mutant":[418],"underwent":[420],"allogeneic":[421],"stem":[422],"cell":[423],"transplantation.":[424],"We":[425],"impact":[429,560],"on":[434,564,589,602,617,665,676,687,698,720,738,755,767,791,811],"chemotherapy.":[438],"Non-responders":[439],"enriched":[444],"RUNX1(26%":[446],"vs.7%,":[447],"p=0.002),":[448],"SRSF2(34%":[449],"vs.19%,":[450],"p=0.045),":[451],"ASXL1":[453],"(18%":[454],"vs.9%,":[455],"p=0.11)":[456],"NPM1":[464],"(24%":[465],"51%,":[467],"p=0.001)":[468],"mutation.":[469],"median":[471],"IDH2":[477],"caseswas":[480],"16.6":[481],"19.1":[483],"months,":[484],"Conclusions:":[486],"young":[489],"appear":[492],"chemo-sensitive":[495],"disease.":[496],"Despite":[497],"excellent":[498],"responses":[500],"non-intensive":[504],"chemotherapy,":[505],"poor":[514],"shorter":[516],"remissions.":[519],"Co-occurring":[520],"RUNX1":[523],"SRSF2":[525],"appeared":[526],"confer":[528],"resistance.":[530],"maintenance":[534],"strategies":[535],"conjunction":[541],"traditional":[543],"offer":[545],"improve":[549],"upon":[550],"MN.":[555],"Future":[556],"studies":[557],"exploring":[558],"early":[562],"transplantation":[563],"IDH1/2mutated":[568],"needed":[571],"Disclosures":[572],"Thota:":[573],"Incyte:":[574,661],"Speakers":[575,578,581,585,613,626,715,730,733,748,800,820],"Bureau.":[576,627,821],"Carraway:Novartis:":[577],"Bureau;":[579,582,586,614,716,731,734,749,801],"Jazz:":[580,714,747],"Agios:":[583],"Consultancy,":[584,718,736,753,765,789,809],"Amgen:":[587,750],"Membership":[588,601,616,664,675,686,697,719,737,754,766,790,810],"entity's":[591,604,619,667,678,689,700,722,740,757,769,793,813],"Board":[592,605,620,668,679,690,701,723,741,758,770,794,814],"Directors":[594,607,622,670,681,692,703,725,743,760,772,796,816],"advisory":[596,609,624,672,683,694,705,727,745,762,774,798,818],"committees;":[597,673,684,695,728,746,763],"FibroGen:":[598],"Consultancy;":[599,655,658,660,713,751,778,782,785,805],"Celgene:":[600,659,674],"committees,":[610,625,799,819],"Research":[611,630,634,639,644,649],"Funding,":[612],"Balaxa:":[615],"Griffiths:Pfizer,":[628],"Inc.:":[629,633,647,788,808],"Funding;":[631,635,640,645],"Novartis,":[632],"Celgene,":[636],"Inc:":[637,781,804],"Honoraria,":[638,643,648],"Astex/Otsuka":[641],"Pharmaceuticals:":[642,777,784],"Alexion":[646,786,806],"Funding.":[650],"Nazha:MEI:":[651],"Consultancy.":[652,662],"Gerds:CTI":[653],"Biopharma:":[654],"Apexx":[656],"Oncology:":[657],"Sekeres:Celgene:":[663],"Opsona:":[685,696],"committees.":[706,775],"Meggendorfer:MLL":[707],"Munich":[708],"Leukemia":[709],"Laboratory:":[710],"Employment.":[711],"Wang:Amgen:":[712],"Pfizer:":[717,752],"Novartis:":[729,732],"Abbvie:":[735,764],"Maciejewski:Apellis":[776],"Ra":[779,802],"Pharmaceuticals,":[780,787,803,807],"Apellis":[783]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2019,"cited_by_count":1}],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2019-01-11T00:00:00"}